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Childhood cancer is relatively rare, representing only about 1% of 
all malignant disease. However, the number of children with cancer 
in the world is expected to increase in parallel with the global 
population. Of the estimated 250 000 children diagnosed with cancer 
every year, about 200 000 live in countries with limited resources; 
their survival rate is estimated to be 25%, while in developed 
countries it approximates 80%.1
It is estimated that there are 50 000 new cases of childhood cancer 
every year in Africa.2 In countries bordering the Mediterranean sea 
and in South Africa (SA) leukaemias are the most frequent cancers in 
children, while in sub-Saharan Africa lymphomas are predominant, 
with Burkitt’s lymphoma (BL) the most common.3-5 Data on survival 
rates in Africa are scarce and the available information is not 
reassuring. Published 5-year survival rates for BL vary from 5% to 
70%,6 with most countries falling within the lower half of the range.
All efforts to improve outcomes in childhood cancer should be 
based on a comprehensive and reliable statistical analysis of the 
situation. In the absence of national cancer registries, let alone 
national paediatric cancer registries (South Africa has the only 
such registry on the continent5), hospital registries may provide the 
required information.
The aim of this study was to analyse the data entered in the register 
of the paediatric haematology oncology unit in Treichville, Côte 
d’Ivoire, from January 1995 to December 2004, as a starting point for 
establishing a strategy to improve the situation of paediatric oncology 
and to evaluate progress over time. The information was grouped 
under patient demographics, types of cancer, delay in diagnosis 
and treatment, modalities of treatment, rate of abandonment of 
treatment, and survival rate.
Côte d’Ivoire is a Francophone African country situated on the 
western part of the continent, with a population of more than 
20 million. Children (under 18 years of age) represent 45% of the 
population. About 43% of all inhabitants live below the poverty line, 
with the annual gross domestic product per capita being US$1 600.7 
There are 14 doctors per 100 000 people.8 Abidjan, with a population 
of 3 310 500, is Côte d’Ivoire’s largest city and commercial and 
banking centre.
The haematology oncology unit of the Department of 
Paediatrics was set up in Treichville (a commune of Abidjan) 
in 1995. It has 20 beds and serves as the referral service for all 
children diagnosed with cancer in Côte d’Ivoire. It also receives 
patients from neighbouring countries (Mauritania, Senegal, Mali, 
Burkina Faso, Guinea and Liberia). The service has a radiology 
facility including a computed tomography (CT) scanner and a 
paediatric surgery division. Not all cases of childhood cancer over 
the study period were histologically confirmed, as there were only 
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10 pathologists in the entire country and only 3 in the University 
Hospital of Treichville in Abidjan.
Chemotherapy was not freely available, the cost of management 
having to be borne by the patients’ families, who often could not 
afford to pay for either the investigations or the medication.
The time period analysed ends just before Treichville joined the 
GFAOP (Groupe Franco-Africain d’Oncologie Pédiatrique – Franco-
African Group of Paediatric Oncology). Treichville became a therapy 
research unit after joining GFAOP, and results obtained after 2004 
will constitute a comparative analysis.
Patients and methods
A retrospective descriptive study of the Treichville paediatric 
haematology oncology unit’s experience was undertaken. All records 
of children (0 - 18 years of age) admitted with a malignancy from 
1 January 1995 to 31 December 2004 were reviewed. Of 405 patients 
who presented to the unit during this time period, 331 were included 
in the study (the remaining folders were incomplete or the diagnosis 
was not confirmed).
Variables analysed included age at diagnosis, gender, urban or 
rural area of residence, clinical presentation, stage of disease, delay in 
diagnosis (defined as the time interval from the onset of symptoms to 
diagnosis), delay in initiation of treatment following diagnosis, loss to 
follow-up, abandonment of therapy, therapeutic protocols and survival.
Staging of BL consisted of chest radiography, abdominal 
ultrasound, bone marrow aspiration (BMA) and trephine biopsy, 
together with laboratory investigations, including cerebrospinal 
fluid examination. Patients had CT scans and all cancers were 
confirmed by biopsy and histopathology.
Staging of nephroblastoma was based on abdominal ultrasound, 
intravenous pyelography and chest radiography.
In acute leukaemia, investigations undertaken included a full blood 
count with smear, BMA and trephine biopsy. Flow cytometry and 
cytogenetic studies were not available, nor were more sophisticated 
investigations such as magnetic resonance imaging, positron emission 
tomography or meta-iodobenzylguanidine scans.
Cure was defined as a remission lasting over 2 years (1 year 
for nephroblastoma).
Ethical approval for the study was obtained from the local ethics 
committee of the University Hospital of Treichville.
Results
The results of 331 children admitted with a malignancy during the 
study period were analysed. Of these, 244 (73.6%) were diagnosed 
with BL and presented with an abdominal mass, 48 patients with 
nephroblastoma (5.7%) constituted the second most common group, 
13 patients (4.5%) were diagnosed with acute leukaemia, and 7 (3.9%) 
had Hodgkin’s disease. The remaining patients had retinoblastoma 
(6 cases), rhabdomyosarcoma (5 cases), neuroblastoma (3 cases), 
and sacrococcygian teratoma, leiomyosarcoma, germ cell tumour, 
haemangioma of the liver and undifferentiated abdominal sarcoma 
(1 case each).
The prevalence of childhood malignancies among the paediatric 
admissions at Treichville doubled over the study period, from 0.32% 
in 1995 to 0.76% in 2004. Table 1 describes the four most common 
malignancies in the study, which represent 96% of all cases.
The sex ratio was 1.35:1 (males 57%, females 43%). Most of the 
patients (78%) lived in urban areas and were between 5 and 10 years 
of age (mean 7.47 years). The most common clinical presentation was 
an abdominal mass (152 cases, 45.9%), followed by swelling of the jaw 
(109, 32.9%); 22 patients (6.6%) had both an abdominal mass and 
swelling of the jaw at presentation.
Only 76% of the patients received treatment. More than half 
(52.6%) of those who were not treated simply could not afford the 
costs, while the remainder died before treatment could be started. 
The chemotherapy protocol used for BL was COPAD modified, 
Table 1. Demographics, staging and outcome of 331 children with the most frequent cancers
Variable Burkitt’s lymphoma Nephroblastoma Leukaemia Hodgkin’s lymphoma
Number of patients, n (%) 244 (73.6) 48 (5.7)  13 (4.5)  7 (3.9) 
Females, % 38.9 56.2 46.1 28.6
Males, % 61.1 43.7 53.8 71.4
Median age, years 7.4 4.1 10.2 8.4
Staging, n (%)
I 14 (5.7) 0 (0)
II 12 (4.9) 8 (16.7)
III 119 (48.8) 9 (18.7)
IV 25 (10.2) 2 (4)
V - 0 (0)
Not staged 74 (30.3) 29 (60.4) 7
Outcome, %        
Cured  6.6  27.1  7.7 0
Still treated 0.8  0 0  0 
Lost to follow-up 50 39.6  46.1  85.7 
Relapsed 2 0 7.7 14.3
Died 40.6 33.3 38.5 0
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consisting of cyclophosphamide 300 mg/m2 on days 1, 2, 4 and 
5, vincristine 1.5 mg/m2 on days 3 and 6, adriamycin 50 mg/m2 
and prednisone 60 mg/m2 on days 1 - 7, and methotrexate given 
intrathecally in a dose of 15 mg on days 1 and 7. Induction 
comprised 3 courses every 2 weeks or as soon as the blood count 
allowed administration of chemotherapy, with consolidation of 
4 monthly courses. The treatment lasted 8 months and the patient 
was considered cured after achieving complete remission without a 
relapse for more than 2 years. Patients were followed up every 2 - 3 
months during the first year after treatment was completed, every 
6 months in the second year and then once a year. Almost half of 
the patients with BL died (40.6%), 50% were lost to follow-up, 2% 
relapsed and only 6.6% were considered cured (0.8% were still on 
treatment at the time of the study).
Of the patients with nephroblastoma, 22.9% had stage III or IV 
disease, and more than 60.5% were not staged. They were treated 
according to the SIOP 2001 protocol.
Almost a third of the patients with nephroblastoma died, 39.6% 
were lost to follow-up, and 27.1% were still alive a year after treatment.
In 61% of cases there was a delay in diagnosis of over 1 month. 
Therapy was instituted within 14 days in 59% of the children treated. 
Delays in commencing treatment were due to waiting for laboratory 
results or histological confirmation, and the families needing time to 
collect the money needed to pay for the chemotherapy.
Almost half of the patients were lost to follow-up after the first 
admission and 39.2% died shortly after the onset of treatment. Only 
9.4% (31 patients) survived in remission for longer than 2 years, a small 
number suffered a relapse (2.1%), and 0.6% were still on treatment.
Discussion
The number of children with cancer increased in Côte d’Ivoire 
over the study period, mirroring experience in the rest of Africa 
and the world. Malignancy in children in West Africa remains 
dominated by BL and nephroblastoma. The survival rate for these 
two malignancies, which are easily diagnosed and respond to 
chemotherapy, exceeds 90% in developed countries. The 1-year 
survival rate for nephroblastoma in this study was 27.1%. The cost of 
treatment for both cancers is also relatively low compared with that of 
treating other malignancies: BL treatment costs around US$509 and 
the cost of treating stage 2 - 3 nephroblastoma, without radiotherapy, 
amounts to US$699.10
Other countries from sub-Saharan Africa report a distribution 
of malignant pathology in children similar to that described in this 
study. Lymphomas represented 41.2% of all malignancies in children 
at the University Teaching Hospital in Enugu, Nigeria, between 1999 
and 2004;11 similarly, in the Tanzanian cancer registry between 1973 
and 1995, lymphomas were the most frequent childhood malignancy 
at 38.9%.12 A different situation is reported from countries in 
northern Africa3,13 and SA,5 where childhood leukaemias are most 
frequent.
In contrast to the major improvement in survival rates for 
childhood cancer in high-income countries and even in Africa,14 
the overall survival rate for Ivoirian children remained low over the 
period studied. However, marked increases in survival for children 
with cancer in low-resource settings have been achieved elsewhere. 
For instance, in most countries in Central America that have 
established twinning programmes and collaborative networks, the 
survival rate of children with acute lymphoblastic leukaemia has risen 
from less than 20% to over 60% over the past decade.15
The urban residence of over 75% of our patients, in contrast to 
an urbanisation level of around 40% for the Ivoirian population 
as a whole, suggests that a number of children with cancer from 
rural areas did not reach the hospital in Treichville. Another 
major hurdle on the path to treatment was the need to pay for 
chemotherapy. This explains why a considerable number of 
patients were not treated, or abandoned their treatment. The 
need to raise money for treatment also contributed to the delay 
between diagnosis and the beginning of therapy. Similar effects 
of such economic constraints have been described in detail in a 
study from Nigeria.16
In 2004 the Paediatric Hematology Oncology Unit in Cote d’Ivoire 
joined the GFAO group.17 As a result, chemotherapy is now free of charge, 
treatment follows established protocols, and access to radiological 
investigations has been opened. This progress in management of 
paediatric malignancies will be the subject of a future study.
The present study makes available for the first time a synthesis of 
the data from the archives of the paediatric haematology oncology 
unit at the University Hospital of Treichville, Côte d’Ivoire. It 
contributes to completing the picture of the numerous challenges, 
many of them socio-economic, encountered in the management of 
children with cancer in Africa. Its main weakness, in common with 
all retrospective studies, is the often incomplete recording of data 
together with the loss of records of some patients.
Conclusions
During its first 10 years of existence, the paediatric haematology 
oncology unit at Treichville admitted more than 400 children with 
various malignancies from Côte d’Ivoire and surrounding countries. 
The most frequent diagnosis in these children was BL, followed by 
nephroblastoma. There was a high rate of abandonment of therapy, 
mainly for financial reasons, resulting in a low rate of cure of only 
6.6% for BL and 27.1% for nephroblastoma (the latter at 1 year of 
follow-up). The unit’s collaboration with the GFAO in 2004 has 
resulted in a progressive improvement in patient management, and 
these more recent outcomes will be reviewed in a future study.
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